A health-care investment firm that’s backing studies of magic mushrooms to treat depression raised $25 million of capital and may consider an initial public offering next year, according to people familiar with the matter.
Atai Life Sciences AG is close to announcing the fundraising with lead backers Christian Angermayer, a German investor, as well as PayPal co-founder Mike Novogratz and Icelandic entrepreneur Thor Bjorgolfsson, said the people, who asked not to be named because the matter isn’t public yet.
Atai owns a substantial stake in U.K. startup Compass Pathways, which is conducting clinical trials of psilocybin, a psychedelic compound ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.